Historical perspectives on the discovery and development of drugs to treat neurological disorders

Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders

Volumn , Issue , 2012, Pages 129-148

  Williams, Michael ^a   Coyle, Joseph T ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865175827     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511980053.008     Document Type: Chapter

References (237)

1. Aisen PS, Schafer KA, Grundman M et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 289:2819–2828.
2. Aizenstein HJ, Nebes RD, Saxton, JA et al. 2008. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509–1517.
3. Albert MS, DeKosky ST, Dickson D et al. 2011. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimer’s Dement, in press.
4. Appel SH, Beers DR, Henkel JS. 2009. T-cell microglia dialogue in Parkinson’s disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 31:7–17.
5. Artemiadis AK, Anagnostouli MC, Alexopoulos EC. 2011. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 36:109–120.
6. Ascherio A, Munger KL. 2007. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61:504–513.
7. Ascherio A, Munger KL. 2010. Epstein–Barr virus infection and multiple sclerosis: a review J Neuroimmune Pharmacol 5:271–277.
8. Atwal JK, Chen Y, Chiu C et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3:84r43.
9. Baker LD, Cross DJ, Minoshima S et al. 2011. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68:51–57.
10. Bartus RT. 2000. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529.
11. Beal MF. 2005. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58:495–505.
12. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. 2009. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease Lancet Neurol 8:67–81.
13. Bender A, Krishnan KJ, Morris CM et al. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38:515–517.
14. Bensimon G, Ludoplh A, Agid Y et al. 2009. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132:156–171.
15. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23.
16. Billia F, Hauck L, Konecny F et al. 2011. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc Natl Acad Sci USA 108:9572–9577.
17. Bjorklund A, Bjorklund T. 2011. Gene therapy for Parkinson’s disease shows promise. Sci Transl Med 3:79ed1.
18. Blum CA, Ellis JL, Loh C et al. 2011. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 54:417–432.
19. Bousquet M, Calon F, Cicchetti F. 2011. Impact of omega-3-fatty acids in Parkinson’s disease. Ageing Res Rev 10:453–463.
20. Braskie MN, Jahnshad N, Stein JL et al. 2011. Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 31: 6764–6770.
21. Brinkmann V, Billich A, Baumruker T et al. 2010. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883–897.
22. Brunden KR, Trojanowski JQ, Lee VMY. 2009. Advances in taufocused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 8:783–793.
23. Bueler H. 2009. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp Neurol 218:235–246.
24. Castellani RJ, Lee H-G, Zhu X et al. 2006. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111:503–509.
25. Castellani RJ, Lee H-G, Zhu X, Perry G, Smith MA. 2008. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67:523–531.
26. Castellano JM, Kim J, Stewart FR et al. 2011. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Translat Med 3:89ra57.
27. Chao J, Yu MS, Ho YS, Wang M, Chang RCC. 2008. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radical Biol Med 45:1019–1026.
28. Chechanover A, Brundin P. 2003. The ubiquitin-proteasome system in neurodegenerative disorders: sometimes the chicken, sometimes the egg. Neuron 40:427–446.
29. Chen J-F, Chern Y. 2011. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Handb Exp Pharmacol 200:267–310.
30. Choi WS, Palmiter RD, Xia Z. 2011. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model. J Cell Biol 192:873–882.
31. Chu J, Pratico D. 2011. 5-Lipoxygenase as an endogenous modulator of amyloid b formation in vivo. Ann Neurol 69:34–46.
32. Citron M. 2010. Alzheimer’s disease: strategies for disease modification Nat Rev Drug Discov 9:387–398.
33. Compston A, Coles A. 2008. Multiple sclerosis. Lancet 372:1502–1517.
34. Coppede F, Migliore L. 2010. Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer’s disease. J Alzheimer’s Dis 20:953–966.
35. Correia SC, Santos RX, Perry G et al. 2011. Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev 10:264–273.
36. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190.
37. Cummings J. 2010. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer’s disease? Biol Psychiatry 68:876–878.
38. de Jong D, Jansen R, Hoefnagels W et al. 2008. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS ONE 3:e1475.
39. DeKosky ST, Carrillo MC, Phelps C et al. 2011. Revision of the criteria for Alzheimer’s disease: a symposium. Alzheimer’s Dement 7:e1–e12.
40. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. 2006. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimer’s Dis 10:89–109.
41. De Meyer G, Shapiro F, Vanderstichele H et al. for the Alzheimer’s Disease Neuroimaging Initiative 2010. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67:949–956.
42. Deng T, Li B, Liu Y et al. 2009. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation and phosphorylation of tau and neurofilaments: relevance to Alzheimer’s disease. Am J Pathol 175:2089–2098.
43. Deng X, Dzamk N, Prescott A et al. 2011. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol 7:203–205.
44. DeTaboada L, Yu J, El-Amouri S et al. 2011. Transcranial laser therapy attenuates amyloid-beta peptide neuropathology in amyloidbeta protein precursor transgenic mice. J Alzheimer’s Dis 23:521–535.
45. Diniz BS, Pinto JA Jr, Forlenz OV. 2008. Do CSF total tau, phosphorylated tau, and b-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9:172–182.
46. Donmez G, Wang D, Cohen DE, Guarente L. 2010. SIRT1 suppresses b-amyloid production by activating the a-secretase gene ADAM10. Cell 142:320–332.
47. Doody RS, Coleb PE, Millerc DS et al. 2011. Global issues in drug development for Alzheimer’s disease. Alzheimer’s Dement 7:197–207.
48. Doody RS, Gavrilova SI, Sano M et al. 2008. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-tomoderate Alzheimer’s disease: a randomised, double-blind, placebocontrolled study. Lancet 372:207–215.
49. Doody RS, Pavlik V, Massman P et al. 2010. Predicting progression of Alzheimer’s disease. Alzheimer’s Res Ther 2:2.
50. Dubois B, Feldman HH, Jacova J et al. 2010. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1124.
51. ECNP Summit Report 2011. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 21:495–499.
52. Elbaz A, Ross OA, Ioannidis JPA et al. 2011. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol 69:778–792.
53. Extance A. 2010. Alzheimer’s failure raises questions about diseasemodifying strategies. Nat Rev Drug Discov 9:749–751.
54. Fagan AM, Mintun MA, Shah AR, Alde P, Roe CM. 2009. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1:371–380.
55. Feany MB. 2010. New approaches to the pathology and genetics of neurodegeneration. Am J Pathol 176:2058–2066.
56. Fernandez HH, Greeley DR, Zweig RM et al. for the 6002-US-051 Study Group 2010. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US 051 trial. Parkinsonism Relat Disord 16:16–20.
57. Feulner TM, Laes SM, Friedrich P et al. 2010. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 15:756–766.
58. Finkbeiner S. 2010. Bridging the valley of death of therapeutics for neurodegeneration. Nat Med 16:1227–1232.
59. Flood DG, Marek GJ, Williams M. 2011. Developing predictive CSF biomarkers – a challenge critical to success in Alzheimer’s disease and neuropsychiatric translational medicine. Biochem Pharmacol 81:1422–1434.
60. Gao HM, Hong JS. 2011. Gene– environment interactions: key to unraveling the mystery of Parkinson’s disease. Prog Neurobiol 94:1–19.
61. Gao X, Chen H, Schwarzschild M, Ascherio A. 2011. Use of ibuprofen and risk of Parkinson’s disease. Neurology 76:863–869.
62. Gasser T. 2010. Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog Brain Res 183:2–20.
63. Geser F, Lee VM, Trojanowski JQ. 2010. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 30:103–112.
64. Geser F, Martinez-Lage M, Trojanowski JQ et al. 2009. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol 256:1205–1214.
65. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 10:918–934.
66. Green RC, Schneider LS, Amato DA et al. 2009. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. J Am Med Assoc 302:2557–2564.
67. Haley RW. 2003. Excess incidence of ALS in young Gulf War veterans. Neurology 61:750–756.
68. Hardy J. 2009. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 110:1129–1134.
69. Harford T. 2011. Positive Black Swans: How to fund research so that it generates insanely great ideas, not pretty good ones. Slate, May 17, 2011. Available at: www. slate.com/id/2293699/pagenum/all/#p2. Accessed August 5, 2011.
70. Hauser RA, Cantillon M, Pourcher E et al. 2011. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, doubleblind, randomised trial. Lancet Neurol 10:221–229.
71. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397.
72. Hollingworth P, Harold D, Sims R et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43:429–435.
73. Holmes C, Boche D, Wilkinson D et al. 2008. Long-term effects of Ab immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223.
74. Holtzman DM, Morris JC, Goate AM. 2011. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3:77sr1/.
75. Hoyer S. 2004. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125.
76. Huang Q, Figueiredo-Pereira ME. 2009. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 15:1292–1311.
77. Hunt CE, Turner AJ. 2009. Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J 276:1854–1859.
78. Huntington’s Disease Collaborative Research Group 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983.
79. Hynd MR, Scott HL, Dodd PR. 2004. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 45:583–595.
80. Iadecola C. 2004. Neurovascular regulation in the normal brain and Alzheimer’s disease. Nat Rev Neurosci 5:347–360.
81. Ilijic E, Guzman JN, Surmeier DJ. 2011. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis 43:364–371.
82. Imbimbo BP, Giardina GA. 2011. g- Secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr Top Med Chem 11:1555–1570.
83. Ioannidis JPA, Panagiotou OA. 2011. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. J Am Med Assoc 305:2200–2210.
84. Ittner LM, Gotz J. 2011. Amyloid-b and tau – a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12:65–72.
85. Jack CR Jr, Albert MS, Knopman DS et al. 2011. Introduction to the recommendations from the National Institute on Aging– Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:257–262.
86. Jack CR Jr, Wiste HJ, Vemuri P et al. 2010. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-toprogression from mild cognitive impairment to Alzheimer’s disease. Brain 133:3336–3348.
87. Jankovic J. 2008. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson’s disease? Ann Neurol 63:267–269.
88. Jarraya B, Boulet S, Ralph SG et al. 2009. Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1:2ra4.
89. Johri A, Chaturvedi, RK, Beal MF. 2011. Hugging tight in Huntington’s. Nat Med 17:245–246.
90. Jucker M. 2010. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 16:1210–1214.
91. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. 2005. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. Br Med J 331:321.
92. Keane PC, Kurzawa M, Blain PG, Morris CM. 2011. Mitochondrial dysfunction in Parkinson’s disease. Parkinsons Dis 2011: art.716871.
93. Khoshnan A, Patterson PH. 2011. The role of IkB kinase complex in the neurobiology of Huntington’s disease. Neurobiol Dis 43:305–311.
94. Kiernan, MC, Vucic S, Cheah BC et al. 2011. Amyotrophic lateral sclerosis. Lancet 377:942–955.
95. Kleinschnitz C, Grund H, Wingler K et al. 2010. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: e1000479.
96. Koch G. 2010. RTMS effects on levodopa-induced dyskinesias in Parkinson’s disease patients: searching for effective cortical targets. Restor Neurol Neurosci 28:561–568.
97. Kolata G. 2010. Years later, no magic bullet against Alzheimer’s disease. New York Times, August 28, 2010. Available at: http://www. nytimes.com/2010/08/29/health/research/29prevent.html. Accessed August 5, 2011.
98. Kurtzke JF, Gudmundsson KR, Bergmann S. 1982. Multiple sclerosis in Iceland: I. Evidence of a postwar epidemic. Neurology 32:143–150.
99. Kurz A, Perneczky R. 2011. Amyloid clearance as a treatment target against Alzheimer’s disease. J Alzheimer’s Dis 24(Suppl. 2): 61–73.
100. Lai BC, Marion SA, Teschke K, Tsui JK. 2002. Occupational and environmental risk factors in Parkinson’s disease. Parkinsonism Relat Disord 8:297–309.
101. Lang AE. 2010. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16:1223–1226.
102. Lee H-G, Zhu X, Castellani RJ et al. 2007. Amyloid-b in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321:823–829.
103. Lemere CA, Masliah E. 2010. Can Alzheimer disease be prevented by amyloid-b immunotherapy? Nat Rev Neurol 6:108–119.
104. Lesage S, Brice A. 2009. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18:R48–R59.
105. LeWitt PA, Rezai AR, Leehey MA et al. 2011. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309–319.
106. Lill CM, Roehr JT, McQueen MB et al. 2011. The PD Gene Database. Alzheimer Research Forum. http://www.pdgene.org/. Accessed August 5, 2011.
107. Lin MT, Beal MF. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795.
108. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong C-X. 2004. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA 101:10804–10809.
109. Liu W, Vives-Bauza C, Acýn-Perez R et al. 2009. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and a-synuclein aggregation in cell culture models of Parkinson’s disease. PLoS ONE 4: e4597.
110. Lovestone S. 2010. Searching for biomarkers in neurodegeneration. Nat Med 16:1371–1372.
111. Luo W, Sun W, Taldone T, Rodina A, Chiosis G. 2010. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 5:24.
112. Maher PA, Schubert DR. 2009. Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother 9:617–630.
113. Maltsev AV, Bystryak S, Galzitskaya OV. 2011. The role of b-amyloid peptide in neurodegenerative diseases. Ageing Res Rev. 10:440–452.
114. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. 2010. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 9:702–716.
115. Maragakis N, Rothstein JD. 2011. New treatments in amyotrophic lateral sclerosis. Neuropsychopharmacology 36:370–372.
116. Marks WJ, Bartus RT, Siffert J et al. 2010. Gene delivery of AAV2- neurturin for Parkinson’s disease: a double blind, randomised, controlled trial. Lancet Neurol 9:1164–1172.
117. Marks WJ, Ostrem JL, Verhagen L et al. 2008. Safety and tolerability of intraputaminal delivery of CERE- 120 (adeno-associated virus serotype 2pneurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 7:400–408.
118. Marrie RA. 2004. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3:709–718.
119. Mattsson N, Zetterberg H, Hansson O et al. 2009. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J Am Med Assoc 302:385–393.
120. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. 2005. Metals and amyloid-beta in Alzheimer’s disease. Int J Exp Pathol 86:147–159.
121. McAlpine FE, Lee JK, Harms AS et al. 2009. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents preplaque amyloid-associated neuropathology. Neurobiol Dis 34:163–177.
122. McElroy JP, Oksenberg JR. 2008. Multiple sclerosis genetics. Curr Topics Microbiol Immunol 318:45–72.
123. McGeer PL, McGeer EG. 2006. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28:639–647.
124. McGeer PL, Rogers J, McGeer EG. 2006. Inflammation, antiinflammatory agents and Alzheimer disease: The last 12 years. J Alzheimer’s Dis 9(Suppl. 3): 271–276.
125. McGeer PL, Steele JC. 2011. The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder. Prog Neurobiol 95:663–669.
126. McKhann GM, Drachman D, Folstein M et al. 1984. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944.
127. McKhann GM, Knopman DS, Chertkow H et al. 2011. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s Dement 7:263–269.
128. McNaught KSP, Olanow CW, Halliwell B, Isacson O, Jenner P. 2001. Failure of the ubiquitin proteasome system in Parkinson’s disease. Nat Rev Neurosci 2:589–594.
129. Meissner WG, Frasier M, Gasser T et al. 2011. Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377–393.
130. Mestre L, Docagne F, Correa F et al. 2009. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40:258–266.
131. Migliore L, Coppede F. 2009. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res/Fund Mol Mechanisms Mutagenesis 667:82–97.
132. Mihaescu R, Detmar SB, Cornel MC et al. 2010. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimer’s Dis 20:967–980.
133. Miller G. 2009. Alzheimer’s biomarker initiative hits its stride. Science 326:386–389.
134. Miners JS, Baig S, Tayler H, Kehoe PG, Love S. 2009. Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 68:902–914.
135. Mitchell AJ. 2009. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 43:411–431.
136. Mitchell JD. 2000. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord 1:235–250.
137. Mitsumoto Y. 2007. Mitochondrial nutrition as a strategy for neuroprotection in Parkinson’s disease – research focus in the Department of Alternative Medicine and Experimental Therapeutics at Hokuriku University. Evid Based Complement AlternatMed 4:263–265.
138. Moreira PI, Santos MS, Seica R, Oliveria CR. 2007. Brain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetes. J Neurol Sci 257:206–214.
139. Morgan D. 2011. Immunotherapy for Alzheimer’s disease. J Intern Med 269:54–63.
140. Morris JC, Price JL. 2001. Pathologic correlates of non demented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci 17:101–118.
141. Morrissette DA, Parachikova A, Green KN, LaFerla FM. 2009. Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 284:6033–6037.
142. Mounsey RB, Teismann P. 2011. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection. Parkinson’s Dis doi:10.4061/2011/617472.
143. Mukherjee, S. 2010. The Emperor of All Maladies. New York: Scribner, pp. 119–122.
144. Naj AC, Jun G, Beecham GW et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with lateonset Alzheimer’s disease. Nat Genet 43:436–441.
145. Nestler EJ, Hyman SE. 2010. Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161– 1169.
146. Obeso JA, Rodriguez-Oroz MC, Goetz CG et al. 2010. Missing pieces in the Parkinson’s disease puzzle. Nat Med 16: 653–661.
147. Obinu MC, Reibaud M, Blanchard V, Moussaoui S, Imperato A. 2002. Neuroprotective effect of riluzole in a primatemodel of Parkinson’s disease: behavioral and histological evidence. Mov Disord 17:3–19.
148. Oehlrich D, Berthelot DJ, Gijsen HJ. 2011. Gamma-secretase modulators as potential disease modifying anti- Alzheimer’s drugs. J Med Chem 54:669–698.
149. Olanow CW, Pruisner SB. 2009. Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci USA 106:12571–12572.
150. Olanow CW, Schapira AHV, LeWitt PA et al. 2006. TCH346 as a neuroprotective drug in Parkinson’s disease: a doubleblind, randomised, controlled trial. Lancet Neurol 5:1013–1020.
151. Olanow CW, Stern MB, Sethi K. 2009. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:S1–S132.
152. Olson L, Humpel C. 2010. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment. Exp Gerentol 45:41–46.
153. Olsson B, Zetterberg H, Hampel H, Blennow K. 2011. Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol 95: 520–534.
154. O’Sullivan SS, Williams DR, Gallagher DA et al. 2008. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106.
155. Palop JJ, Mucke L. 2010. Amyloidbeta- induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13:812–818.
156. Panza F, Frisardi V, Imbimbo BP et al. 2010. Bapineuzumab: anti-bamyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy 2: 767–782.
157. Parkinson Study Group PRECEPT Investigators 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480–1490.
158. Pertwee RG. 2002. Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165–174.
159. Peterson LK, Fujinami RS. 2007. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 184:37–44.
160. Popper K. 2002. The Logic of Scientific Discovery. London: Routledge.
161. Powers KM, Kay DM, Factor SA et al. 2008. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 23:88–95.
162. Prokesch S. 2011. The reluctant social entrepreneur. Harvard Business Rev June, 2011. [Prod. #:BR1106-MAGENG.]
163. Ptolemy AS, Rifai N. 2010. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scan J Clin Lab Invest 70(Suppl. 242):6–14.
164. Querfurth HW, LaFerla FM. 2010. Alzheimer’s disease. N Engl J Med 362:329–344.
165. Qui WQ, Folstein MF. 2006. Insulin, insulin-degrading enzyme and amyloid-b peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 27:190–198.
166. Rabinovici GD, Furst AJ, Neil JP et al. 2007. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205–1212.
167. Rabinovici G, Miller B. 2010. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24:375–398.
168. Raina P, Santaguida P, Ismaila A et al. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379–397.
169. Rascol O, Blin O, Thalamas C et al. 1999. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson’s disease. Ann Neurol 45:736–741.
170. Rascol O, Fitzer-Attas CJ, Hauser R et al. 2011. A double-blind, delayedstart trial of rasagiline in Parkinson’s disease (the ADAGIO study): pre-specified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10:415–423.
171. Rascol O, Nutt JG, Blin O et al. 2001. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58:249–254.
172. Readnower RD, Sauerbeck AD, Sullivan PG. 2011. Mitochondria, amyloid b, and Alzheimer’s disease. Int J Alzheimer’s Dis 22: art.104545.
173. Reichling DB, Levine JD. 2011. Pain and death: neurodegenerative disease mechanism in the nociceptor. Ann Neurol 69:13–21.
174. Reines SA, Block GA, Morris JC et al. 2004. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66–71.
175. Richardson PJ, Kase H, Jenner PG. 1997. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson’s disease. Trends Pharmacol Sci 18:338–344.
176. Richardson RM, Kells AP, Rosenbluth KH et al. 2011. Interventional MRIguided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson’s disease. Mol Ther doi:10.1038/mt.2011.11.
177. Rodrigues R, Bonda DJ, Perry G et al. 2010. Oxidative stress and neurodegeneration: an inevitable consequence of aging? Implications for therapy. In Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Ritsner MS, ed. New York: Springer, pp. 305–323.
178. Rogers J, Kirby LC, Hempelman SR et al. 1993. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43:1609–1611.
179. Rogers N, Paine S, Bedford L, Layfield R. 2010. The ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration. Neuropathol Appl Neurobiol 36:113–124.
180. Ross GW, Abbott RD, Petrovitch H et al. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. J Am Med Assoc 283:2674–2679.
181. Sabbagh MN, Berk C. 2010. Latrepirdine for Alzheimer’s disease: trials and tribulations. Fut Neurol 5:645–665.
182. Saporito MS, Hudkin RL, Maroney A. 2002. Discovery of CEP-1347/KT- 7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem 40:23–62.
183. Sastre M, Gentleman SM. 2010. NSAIDs: how they work and the prospects as therapeutics in Alzheimer’s disease. Front Aging Neurosci 2:20.
184. Satake W, Nakabayashi Y, Mizuta I et al. 2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307.
185. Schapira AHV. 2007. Mitochondrial dysfunction in Parkinson’s disease. Cell Death Differ 14:1261–1266.
186. Schapira AHV. 2010. Neuroprotection in Parkinson’s disease. Blue Books Neurol 34:301–320.
187. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. 2011. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care doi: 10.2337.
188. Schneider SA, Bhatia KP, Hardy J. 2009. Complicated recessive dystonia parkinsonism syndromes. Mov Disord 24:490–499.
189. Schon EA, DiMauro S, Hirano M, Gilkerson RW. 2010. Therapeutic prospects for mitochondrial disease. Trends Mol Med 16:268–276.
190. Schor NF. 2011. What the halted phase III g-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69:237–239.
191. Shults CW, Oakes D, Kieburtz K et al. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550.
192. Schwarzschild MA, Agnati L, Fuxe K, Chen J-F, Morelli M. 2006. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 29:647–654.
193. Selkoe D. 2011. Dennis Selkoe on the amyloid hypothesis of Alzheimer’s disease. Science Watch. March, 2011. Available at: http://sciencewatch.com/ana/st/alz2/11marSTAlz2Selk1/. Accessed August 5, 2011.
194. Serafini B, Severa M, Columba- Cabezas S et al. 2010. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 69:677–693.
195. Shaw LM, Vanderstichele H, Knapik- Czajka M et al. 2009. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative studies. Ann Neurol 65:403–413.
196. Sherer TB. 2011. Biomarkers for Parkinson’s disease. Sci Transl Med 3:79ps14.
197. Shi JQ, Shen W, Chen J et al. 2011a. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 1368:239–247.
198. Shi M, Bradner J, Hancock AM et al. 2011b. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580.
199. Simón-Sánchez J, Schulte C, Bras JM et al. 2009. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41: 1308–1312.
200. Soininen H, West C, Robbins J, Niculescu L. 2007. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord 23:8–21.
201. Soscia SJ, Kirby JE, Washicosky KJ et al. 2010. The Alzheimer’s diseaseassociated amyloid beta-protein is an antimicrobial peptide. PLoS One 3:e9505.
202. Sperling RA, Aisen PS, Beckett LA et al. 2011. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association Workgroup. Alzheimer’s Dement 7:280–292.
203. Stacy M, Silver D, Mendis T et al. 2008. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:2233–2240.
204. Steen E, Terry BM, Rivera EJ et al. 2005. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer’s disease – is this type 3 diabetes? J Alzheimer’s Dis 7:63–80.
205. Swardfager W, Lanctot K, Rothenburg L et al. 2010. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 68:930–941.
206. Takeda S, Sato N, Uchio-Yamada K et al. 2010. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Ab deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107:7036–7041.
207. Thacker EL, O’Reilly EJ, Weisskopf MG et al. 2007. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68:764–768.
208. Thies W. 2011. Stopping a thief and killer – Alzheimer’s disease crisis demands greater commitment to research. Alzheimer’s Dement 7:175–176.
209. Thies W, Bleiler L. 2011. Alzheimer’s Association Report: 2011 Alzheimer’s disease facts and figures. Alzheimer’s Dement 7:208–244.
210. Tobinick EL, Gross H. 2008a. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 8:27.
211. Tobinick EL, Gross H. 2008b. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 5:2.
212. Toulouse A, Sullivan AM. 2008. Progress in Parkinson’s disease – where do we stand? Prog Neurobiol 85:376–392.
213. Tranah GJ. 2011. Mitochondrialnuclear epistasis: implications for human aging and longevity. Ageing Res Rev 10:238–252.
214. Trist DG. 2011. Scientific process, pharmacology and drug discovery. Curr Opin Pharmacol. 11: 528–537.
215. U.S.–Venezuela Collaborative Research Project, Wexler NS. 2004. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 101:3498–3503.
216. Van Broeckhoven C. 2010. The future of genetic research on neurodegeneration. Nat Med 16:1215–1217.
217. Volonte C, Amadio S, Cavaliere F et al. 2003. Extracellular ATP and neurodegeneration. Curr Drug Target CNS Neurol Disord 2:403–412.
218. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. 2006. Recent clinical failures in Parkinson’s disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72:1197–1206.
219. Waldmeier P, Spooren WP, Hengerer B. 2000. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson’s disease. Naunyn-Schmideber’s Arch Pharmacol 362:526–537.
220. Weksler ME, Gouras G, Relkin NR, Szabo P. 2005. The immune system, amyloid-beta peptide, and Alzheimer’s disease. Immunol Rev 205:244–256.
221. Weydt P, Soyal SM, Gellera C et al. 2009. The gene coding for PGC-1a modifies age at onset in Huntington’s Disease. Mol Neurodegener 4:3.
222. Wijesekera LC, Leigh PN. 2009. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4:3.
223. Wilcock GK. 2010. Bapineuzumab in Alzheimer’s disease: where now? Lancet Neurol 9:134–136.
224. Williams M. 2009. Progress in Alzheimer’s disease drug discovery: an update. Curr Opin Invest Drugs 10:23–34.
225. Wischik CM, Wischik DJ, Storey JMD, Harrington CR. 2010. Rationale for tau aggregation inhibitor therapy in Alzheimer’s disease and other taopathies. In Emerging Drugs and Targets for Alzheimer’s Disease, Vol. 1, Beta-Amyloid, Tau Protein, and Glucose Metabolism. Martinez A, ed. RSC Drug Discovery Series. Cambridge: Royal Chemical Society, pp. 210–232.
226. Wong E, Cuervo AM. 2010. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 13:805–811.
227. World Alzheimer Report 2009. London, UK: Alzheimer’s Disease International. Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed August 5, 2011.
228. Wu Y, Le W, Jankovic J. 2011. Preclinical biomarkers of Parkinson disease. Arch Neurol 68:22–30.
229. Xu K, Bastia E, Schwarzschild M. 2005. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson’s disease. Pharmacol Ther 105:267–310.
230. Yang J-L, Weissman L, Bohr VA, Mattson MP. 2008. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 7:1110–1120.
231. Yu TJ, Zhang Y, Kenricj M et al. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3:84ra44.
232. Zajicek JP, Apostu VI. 2011. Role of cannabinoids in multiple sclerosis. CNS Drugs 25:187–201.
233. Zetterberg Z, Mattsson N, Blennow K, Olsson B. 2010. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer’s Res Ther 2:32.
234. Zhao L, Teter B, Morihara T. 2004. Insulin-degrading enzyme as a downstreamtarget of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24:11120–11126.
235. Zheng B, Liao Z, Locascio JJ et al. 2010. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2:52ra73.
236. Zhou Q, Sumbria R, Hui EK-A et al. 2011. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther 339: 618–623.
237. Zuccato C, Valenza M, Cattaneo C. 2010. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90:905–981.